Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo ABORXOY 37 Debt-to-Equity is 0.04 as of Jun. 2026, which is 96% below its 10-year median of 1.02. GuruFocus rates ORXOY with a GF Score™ of 37/100 and a GF Value™ of $0.31 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, Orexo AB ranks better than 85.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Orexo AB's Debt-to-Equity or its related term are showing as below:
ORXOY'
s Debt-to-Equity Range Over the Past 10 Years
Min: -21.84 Med: 1.02 Max: 19.96
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Orexo AB was 19.96. The lowest was -21.84. And the median was 1.02.
ORXOY's Debt-to-Equity is ranked better than 85.2% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ORXOY: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Orexo AB Debt-to-Equity Related Terms
Orexo AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Orexo AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Orexo AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOY) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orexo AB and its competitors. This is 96% below median its historical median of 1.02. According to the industry distribution chart, Orexo AB ranks #120 out of 811 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Orexo AB's Debt-to-Equity too high?
Orexo AB's current Debt-to-Equity of 0.04 is 96% below median its 10-year median of 1.02. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Orexo AB's value of 0.04 is 85.2% below this industry median. Based on the distribution chart, Orexo AB ranks #120 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #120 out of 811 companies for Debt-to-Equity. This places Orexo AB in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Orexo AB's value of 0.04 is 85.2% below this benchmark. While the company's 10-year median is 1.02 vs. the industry median of 0.27, Orexo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Debt-to-Equity of 0.04 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Debt-to-Equity is 0.04, which is 96% below median its own 10-year median of 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $1.77 — trading 471% above its estimated fair value. The current Debt-to-Equity is 0.04, which is 96% below median its 10-year median of 1.02 and 85.2% below the Drug Manufacturers industry median of 0.27. Orexo AB's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOY) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $1.77 is trading 471% above its estimated GF Value™ of $0.31.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOY:
Debt-to-Equity: 0.04 (96% below median its 10-year median of 1.02)
GF Value™: $0.31 vs. price of $1.77 (471% above fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#120 of 811)
No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score
Get the complete analysis for ORXOY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOY has been successfully added to your 
